17
Participants
Start Date
March 22, 2021
Primary Completion Date
April 17, 2024
Study Completion Date
April 17, 2024
tucatinib
300 mg given twice daily orally
trastuzumab
6 mg/kg loading dose will be administered intravenously (IV; into the vein) on Cycle 1 Day 1, followed by 4 mg/kg IV on Cycle 1 Day 15 and then Days 1 and 15 of each cycle thereafter
ramucirumab
8 mg/kg will be administered IV on Days 1 and 15 of each cycle
paclitaxel
60 or 80 mg/m\^2 IV on Days 1, 8, and 15 of each cycle
tucatinib placebo
Given twice daily orally
trastuzumab placebo
IV on Days 1 and 15 of each cycle
Kaohsiung Medical University Hospital, Kaohsiung City
Central Coast Local Health District (Gosford and Wyong Hospitals), Gosford
National Taiwan University Hospital, Taipei
Taipei Veterans General Hospital, Taipei
Seoul National University Bundang Hospital, Seongnam-si
Roswell Park Cancer Institute, Buffalo
Allegheny General Hospital, Pittsburgh
Ajou University Hospital, Suwon
University of Pennsylvania / Perelman Center for Advanced Medicine, Philadelphia
Lombardi Cancer Center / Georgetown University Medical Center, Washington D.C.
Duke University Medical Center, Durham
University of Alabama at Birmingham, Birmingham
Tennessee Oncology-Nashville/Sarah Cannon Research Institute, Nashville
University of Tennessee, Knoxville
Norton Cancer Institute, Louisville
Kyungpook National University Chilgok Hospital, Daegu
Cleveland Clinic - Taussig Cancer Institute, Cleveland
Dong-A University Hospital, Busan
Holden Comprehensive Cancer Center / University of Iowa, Iowa City
Minnesota Oncology Hematology P.A., Saint Paul
University of Chicago Medical Center, Chicago
Texas Oncology - Baylor Sammons Cancer Center, Dallas
Texas Oncology - Tyler, Tyler
Texas Oncology - San Antonio Medical Center, San Antonio
Rocky Mountain Cancer Centers - Aurora, Aurora
SCL Health Good Samaritan Medical Center Cancer Centers of Colorado, Lafayette
Lutheran Medical Center - Cancer Centers of Colorado, Wheat Ridge
Cancer Centers of Colorado - Denver, Denver
SCL Health - St. Mary's Hospital & Medical Center, Grand Junction
Huntsman Cancer Institute/University of Utah, Salt Lake City
Mayo Clinic Arizona, Phoenix
Arizona Cancer Center / University of Arizona, Tucson
Comprehensive Cancer Centers of Nevada, Las Vegas
UCLA Medical Center / David Geffen School of Medicine, Santa Monica
City of Hope National Medical Center, Duarte
Oncology Associates of Oregon, Eugene
Northwest Cancer Specialists, P.C., Vancouver
Dana Farber Cancer Institute, Boston
Austin Health, Heidelberg
London Regional Cancer Program, London Health Sciences Centre, London
Centre Hospitalier de l'Universite de Montreal, Montreal
McGill University Department of Oncology / McGill University Health Centre, Montreal
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Center - Oncology, Seoul
Samsung Medical Center, Seoul
Sarah Cannon Research Institute UK, London
The Christie NHS Foundation Trust, Manchester
Seagen Inc.
INDUSTRY